CVRx (CVRX) Receives Proposal to Retain Barostim Procedure Classification; Analysts Forecast $11.80 Average Price Target

CVRx has received a proposal from CMS to maintain the Barostim implant procedure within the New Technology Ambulatory Payment Classification, including an outpatient setting payment of around $45,000 per procedure. The company anticipates the final rule for the 2026 Medicare Hospital Outpatient Prospective Payment System to be released in November, with implementation expected on January 1, 2026. Wall Street analysts forecast an average target price of $11.80, with an upside of 66.20% from the current price of $7.10.

CVRx, Inc. (NASDAQ: CVRX), a commercial-stage medical device company, has received a proposal from the Centers for Medicare and Medicaid Services (CMS) to maintain the Barostim implant procedure within the New Technology Ambulatory Payment Classification (APC) 1580. The proposed payment for outpatient procedures is approximately $45,000. This move is expected to enhance the financial viability of the procedure and support its broader market adoption.

The proposal follows two recent positive developments for Barostim. As of October 1, 2024, Barostim was assigned to a higher paying MS-DRG for inpatient procedures. Additionally, it is set to transition from Category III to Category I CPT codes for physician payments starting January 1, 2026. These updates underscore the clinical value of Barostim and reinforce its role in heart failure care.

The company anticipates the final rule for the 2026 Medicare Hospital Outpatient Prospective Payment System (OPPS) to be released in November, with implementation expected on January 1, 2026. This final rule may differ from the proposed rule, potentially affecting reimbursement and access to the Barostim implant procedure.

Wall Street analysts have issued a median target price of $11.80 for CVRX, with an upside of 66.20% from the current price of $7.10. This indicates a positive outlook on the company's future performance.

The Barostim implant procedure involves an implantable device that delivers electrical pulses to improve heart failure symptoms. The device is FDA-approved and holds CE Mark approval for heart failure and resistant hypertension in the U.S. and the European Economic Area.

Despite the positive developments, the company's reliance on proposed CMS reimbursement rates introduces uncertainty. Forward-looking statements indicate risks and uncertainties that could lead to results differing from expected outcomes.

References:
[1] https://www.nasdaq.com/articles/cvrx-inc-announces-proposed-cms-payment-barostim-implant-procedure-support